Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer

被引:21
作者
Cohen, RJ
Cooper, K
Haffejee, Z
Robinson, E
Becker, PJ
机构
[1] S AFRICAN INST MED RES,SCH PATHOL,JOHANNESBURG 2000,SOUTH AFRICA
[2] UNIV WITWATERSRAND,JOHANNESBURG 2050,SOUTH AFRICA
[3] UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND
[4] MRC,DEPT BIOSTAT,CAPE TOWN,SOUTH AFRICA
关键词
prostate cancer; p53; c-myc; c-erbB-2; bet-2; neuroendocrine cells; tumor grade and tumor stage;
D O I
10.1080/00313029500169033
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The progression of prostatic adenocarcinoma from localized disease to metastatic carcinoma appears to be a multi-step sequence. The expression of common oncogenes/oncosuppressor genes and the mediating effect of neuroendocrine tumor cells may play a role in this progression. The expression of the more frequently investigated oncogenes/oncosuppressor genes (p53, c-myc, c-erbB-2, bcl-2) and the presence of neuroendocrine cells were assessed in prostatic cancer tissue from patients with localized and metastatic cancer. These oncogenes/oncosuppressor genes were evaluated according to tumor stage and grade and their relationship to one another. Grade was not related to any of the oncogene markers or to the presence of neuroendocrine cells. Advancing stage was associated with a significant increase in p53 expression, while other markers remained constant in all stages. Neuroendocrine cells, p53, c-myc, c-erbB-2 and bcl-2 were rarely co-expressed at any stage of prostate cancer.
引用
收藏
页码:229 / 232
页数:4
相关论文
共 25 条
[1]   IMMUNOHISTOCHEMICAL DETERMINATION OF P53 PROTEIN NUCLEAR ACCUMULATION IN PROSTATIC ADENOCARCINOMA [J].
APRIKIAN, AG ;
SARKIS, AS ;
FAIR, WR ;
ZHANG, ZF ;
FUKS, Z ;
CORDONCARDO, C .
JOURNAL OF UROLOGY, 1994, 151 (05) :1276-1280
[2]   PROSTATIC-CARCINOMA - A MULTIVARIATE-ANALYSIS OF PROGNOSTIC FACTORS [J].
BERNER, A ;
HARVEI, S ;
TRETLI, S ;
FOSSA, SD ;
NESLAND, JM .
BRITISH JOURNAL OF CANCER, 1994, 69 (05) :924-930
[3]  
BROOKSTEIN R, 1993, CANCER S, V71, P1179
[4]   ENHANCED EXPRESSION OF THE C-MYC PROTOONCOGENE IN HIGH-GRADE HUMAN-PROSTATE CANCERS [J].
BUTTYAN, R ;
SAWCZUK, IS ;
BENSON, MC ;
SIEGAL, JD ;
OLSSON, CA .
PROSTATE, 1987, 11 (04) :327-337
[5]   NEUROENDOCRINE CELLS - A NEW PROGNOSTIC PARAMETER IN PROSTATE-CANCER [J].
COHEN, RJ ;
GLEZERSON, G ;
HAFFEJEE, Z .
BRITISH JOURNAL OF UROLOGY, 1991, 68 (03) :258-262
[6]   PROSTATIC-CARCINOMA - HISTOLOGICAL AND IMMUNOHISTOLOGICAL FACTORS AFFECTING PROGNOSIS [J].
COHEN, RJ ;
GLEZERSON, G ;
HAFFEJEE, Z ;
AFRIKA, D .
BRITISH JOURNAL OF UROLOGY, 1990, 66 (04) :405-410
[7]  
COHEN RJ, 1992, ARCH PATHOL LAB MED, V116, P65
[8]   FREQUENCY AND CHARACTERIZATION OF P53 MUTATIONS IN PRIMARY AND METASTATIC HUMAN PROSTATE-CANCER [J].
DINJENS, WNM ;
VANDERWEIDEN, MM ;
SCHROEDER, FH ;
BOSMAN, FT ;
TRAPMAN, J .
INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (05) :630-633
[9]   PREDICTION OF PROGNOSIS FOR PROSTATIC ADENOCARCINOMA BY COMBINED HISTOLOGICAL GRADING AND CLINICAL STAGING [J].
GLEASON, DF ;
MELLINGE.GT .
JOURNAL OF UROLOGY, 1974, 111 (01) :58-64
[10]  
Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171